Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 ...

The field of perinatal mental health is increasingly acknowledging the significant influence of maternal endocrine and metabolic disorders on psychological ...